U.S. Professional Services Stock News

With no single headline event driving attention today, JBS (NYSE:JBS) is drawing interest as investors look at its recent share moves and its sizeable global meat processing footprint across beef, pork, poultry, and prepared foods. See our latest analysis for JBS. JBS’s recent 7 day share price return of 13.01% and 90 day share price return of 17.53%, with the stock now at $17.03, suggest momentum has picked up after a quieter 30 day share price return of 0.83%. If the JBS move has you...

Hawaiian Electric Industries (NYSE:HE) has agreed to a $100 million settlement to resolve significant stockholder derivative lawsuits. The payment will be funded by insurers and also partially settles a related securities class action. The agreement is subject to final court approval, with upcoming hearings expected to clarify the remaining legal process. For shareholders watching NYSE:HE at a current share price of $14.67, this settlement addresses a key source of legal uncertainty. The...

If you are wondering whether Viavi Solutions at US$34.64 is still attractively priced after a big run, the key question is what that price actually reflects about the business. The stock has delivered returns of 3.1% over the past week, 16.6% over the past month, 90.9% year to date and 209.6% over the last year, with a 225.3% return over three years and 114.0% over five years, which puts recent valuation questions front and center. Recent coverage has focused on Viavi Solutions as a...

Palvella Therapeutics (NasdaqCM:PVLA) has appointed Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services. McDonough has extensive experience launching and commercializing therapies for rare skin diseases, including work on VYJUVEK®. The appointment is intended to support Palvella’s commercial readiness as QTORIN™ rapamycin advances through late-stage trials. For investors watching rare disease drug developers, Palvella Therapeutics sits at the intersection of...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Morningstar...

AnaptysBio has approved the spin off of First Tracks Biotherapeutics, with shareholders set to receive one First Tracks share for each AnaptysBio share held. First Tracks Biotherapeutics is expected to list on Nasdaq and will be funded through capital from AnaptysBio and a private placement. The company has added experienced industry executive Susannah Gray to its board as part of the transition. The spin off comes as AnaptysBio, listed as NasdaqGS:ANAB, is in focus with a current share...

Over the last 7 days, the United States market has experienced a 1.9% decline, yet it remains up by 15% over the past year with anticipated earnings growth of 15% annually in the coming years. In this dynamic environment, identifying promising small-cap stocks with insider buying can offer unique opportunities for investors seeking potential value amidst fluctuating market conditions.

Over the last 7 days, the United States market has experienced a 1.9% decline, yet it remains up by 15% over the past year with earnings projected to grow by 15% annually. In such conditions, identifying stocks that may be trading below their intrinsic value can present potential opportunities for investors seeking to capitalize on undervalued assets in a growing market.

Over the last 7 days, the United States market has dropped 1.9%, while showing a notable 15% rise over the past year, with earnings expected to grow annually by the same percentage. In such a fluctuating market, identifying stocks with strong fundamentals and growth potential becomes crucial for investors seeking stability and opportunity. Penny stocks, though an older term, still signify smaller or emerging companies that can offer significant value; when these companies have solid...

Palo Alto Networks, Inc. ( NASDAQ:PANW ) shareholders (or potential shareholders) will be happy to see that the...

The Morning Bull - US Market Morning Update Monday, Mar, 30 2026 US stock futures are pointing higher this morning, with E-mini S&P 500 contracts up about 0.5%, as investors weigh rising government bond yields against mixed signals on consumer confidence. The US 10 year yield sits near 4.4%, which means borrowing costs for mortgages, credit cards and companies remain relatively expensive. At the same time, the University of Michigan consumer sentiment index is revised down to 53.3, while...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Regions Financial (NYSE:RF) has proposed amendments to its Certificate of Incorporation ahead of its upcoming annual meeting. The changes include eliminating certain supermajority voting provisions and removing specific business combination restrictions. The Board is also seeking to limit the liability of officers as permitted by Delaware law and introduce other governance updates. For investors watching NYSE:RF, these governance proposals come with the stock recently trading at $25.16...

Despite announcing strong earnings, GDS Holdings Limited's ( NASDAQ:GDS ) stock was sluggish. We think that the market...

OceanPal Inc. ( NASDAQ:SVRN ) insiders who purchased shares in the last 12 months were richly rewarded last week. The...

How RBC Bearings' Valuation Stacks Up Against Its Market Price With RBC Bearings' share price around US$532.25, many investors are asking the same question: is the stock pricing in too much optimism, or are markets still underestimating its potential? Recent returns are mixed, with a 0.9% decline over the last 7 days and a 7.6% decline over the last 30 days, set against a 16.0% gain year to date and a 65.4% return over the past year. These moves sit in the context of RBC Bearings' longer term...

For investors considering whether Artivion at around US$35 per share still offers value or whether the recent run has already priced in the story, this article breaks down what the current market price might be implying. The stock has pulled back over the last week and month, with declines of 1.2% and 8.3%, respectively, while still sitting on a 43.6% return over 1 year and 176.1% over 3 years. Recent coverage has focused on Artivion's position in the medical equipment space and investor...

If you are wondering whether Bright Horizons Family Solutions at US$77.99 is priced attractively or asking too much for its prospects, the valuation picture is not as straightforward as the share price alone might suggest. The stock has seen a 4.7% gain over the past 30 days, but that sits against a 21.5% decline year to date and a 38.6% decline over the past year, which can shift how the market views both risk and potential reward. Recent coverage has focused on the company within the...

In March 2026, Novanta Inc. announced it had joined the NVIDIA Halos AI Systems Inspection Lab, an ANAB-accredited facility focused on validating AI-driven physical systems, to align its motion control and sensing technologies with NVIDIA safety platforms such as NVIDIA IGX Thor. This collaboration aims to make it easier for robotics and physical AI equipment makers to certify warehouse automation, industrial robotics, and emerging humanoid platforms by ensuring Novanta’s hardware and...

SELLAS Life Sciences Group, Inc. filed a US$150 million at-the-market follow-on equity offering alongside a broad omnibus shelf registration covering common and preferred stock, debt securities, warrants, and units, shortly after reporting a narrower full-year 2025 net loss of US$26.86 million and lower basic loss per share. At the same time, SELLAS is highlighting preclinical data for its CDK9 inhibitor SLS009 in acute myeloid leukemia, including activity in mutation-heavy models often...

In March 2026, Kanzhun Limited reported past fourth-quarter and full-year 2025 results showing higher revenue and net income, issued first-quarter 2026 revenue guidance, approved a new annual dividend policy, and expanded its share repurchase authorization to US$400 million through August 28, 2027. The decision to return at least half of adjusted net income over the next three years via dividends and buybacks highlights a stronger emphasis on capital returns alongside Kanzhun’s core online...

Why Andersons Stock Is On Investors’ Radar Andersons (ANDE) has drawn attention after a period of strong share price performance, with the stock showing double digit total returns over the past year and the past three months. See our latest analysis for Andersons. With the share price at $73.19, Andersons has seen strong momentum, with a 10.16% 7 day share price return and a 12.10% 30 day share price return. The 1 year total shareholder return of 72.35% highlights how sustained this trend has...

TPG (TPG) shares were in focus after reports that OpenAI is in advanced talks with the firm and other private equity groups to create a joint venture to distribute OpenAI’s enterprise products. See our latest analysis for TPG. The OpenAI talks arrive during a weak patch for TPG’s share price, which has a 1 month share price return of 9.95% and a year to date share price return of 40.53%, even though the 3 year total shareholder return is 49%. This suggests that longer term holders have still...

Rocket Pharmaceuticals (RCKT) is back in focus after the FDA granted accelerated approval for its gene therapy KRESLADI to treat pediatric patients with severe leukocyte adhesion deficiency I who lack matched sibling donors. See our latest analysis for Rocket Pharmaceuticals. Even with the FDA approval and accompanying priority review voucher, Rocket Pharmaceuticals’ recent share price performance has been weak, with a 1-month share price return of a 24.75% decline and a 1-year total...